Cero Therapeutics’ first patient completes dose-limiting toxicity observation

The company states: “CERo Therapeutics (CERO) announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial’s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.” CERo CMO Robert Sikorski MD., PhD. noted, “The first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML patient. A second AML patient has been identified and has provided informed consent for participation in the trial.”